WhiteLab Genomics has raised $26 million in Series B financing to accelerate the development of AI-designed components for genomic medicines and expand its international commercial footprint. The round was led by AVP, with new investors Yaday Health and Blast Club joining existing backers Omnes Capital and Debiopharm Innovation Fund. The Paris- and Boston-based TechBio company said the capital will support in vivo validation programs, new bio-asset development, and growth across North America, Europe, and Asia.
Financing Supports In Vivo Validation
The new funding will be directed toward validating WhiteLab’s technologies across viral and non-viral delivery systems as well as programmable genetic payloads. The company aims to create a portfolio of experimentally validated bio-assets that can be advanced independently or alongside pharmaceutical and biotechnology partners. Its strategy centers on reducing the time and trial-and-error typically required to design genetic medicines with the delivery characteristics needed for therapeutic development.
AI Platform Targets Delivery Challenges
WhiteLab’s proprietary platform, ALFRED, uses artificial intelligence to guide the design and optimization of delivery systems for cell and gene therapies. The company combines computational design with experimental and in vivo testing in an effort to identify promising candidates earlier in the development process. Its work spans adeno-associated viruses, lipid nanoparticles, and synthetic genetic elements designed to control where and when therapeutic genes are expressed.
Brain Delivery Results Highlight Platform Potential
WhiteLab has already tested its approach in the central nervous system through research conducted with the Paris Brain Institute. According to the company, AI-designed AAV candidates were able to cross the blood-brain barrier in in vivo studies while showing a strong brain-to-liver targeting ratio and no detectable liver signal. The findings are intended to support future applications in neurological diseases, rare genetic disorders, and brain cancers where targeted delivery remains a major development challenge.
Commercial Expansion Across Key Markets
The Series B will also support WhiteLab’s commercial expansion, particularly in the United States and Asia. The company plans to strengthen its Boston operations, build a larger presence on the U.S. West Coast, and pursue opportunities in Japan and South Korea while continuing to grow in Europe. These efforts are designed to deepen relationships with biopharma companies seeking differentiated genomic medicine assets and delivery technologies.
Board Strengthened for Next Growth Phase
WhiteLab is also expanding its Board of Directors as it enters its next stage of development. François Robinet, managing partner at AVP, and Dr. Daniel Teper, managing partner at Yaday Health and founder and CEO of NAYA Therapeutics, have joined the board following the financing. Their appointments add investment and biotechnology experience as the company moves from platform development toward a broader portfolio of validated assets and partnerships.
Partnerships and Upcoming Data
Founded in 2019, WhiteLab works with industrial and academic organizations including Sanofi, Cytiva, the University of Massachusetts, the Vision Institute in Paris, and the Paris Brain Institute. The company is also preparing to present additional data from collaborations involving Sanofi, Cytiva, the Paris Brain Institute, and Institute Imagine at the European Society of Gene and Cell Therapy Annual Congress. Those presentations are expected to provide further evidence on the in vivo performance of WhiteLab’s AI-designed candidates.
With the Series B financing, WhiteLab Genomics is positioning itself to move beyond computational discovery and build a larger pipeline of experimentally validated genomic medicine components. The company is combining AI-guided design, laboratory testing, and in vivo validation while expanding its commercial reach in major biotechnology markets. Its next phase will focus on turning that integrated platform into differentiated bio-assets that can be developed internally or through partnerships with drug developers.